Major drugs to be hit by Colombian price cuts
This article was originally published in SRA
Major products from leading multinationals are to have their prices reduced in Colombia by an average of 40%, in an effort to bring their price levels more into line with those in international markets.
You may also be interested in...
While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.